Found 161 articles for: "ustekinumab"
Treatment of Severe Psoriasis With Ustekinumab During Pregnancy
October 2012 | Volume 11 | Issue 10 | Case Reports | 1240 | Copyright © October 2012
We present the case of a female, aged 22 years, with a long history of recalcitrant pustular psoriasis and psoriatic arthritis, treated with ustekinumab during pregnancy. The result of treatment was a...
Read MorePSOLAR: Design, Utility, and Preliminary Results of a Prospective, International, Disease-Based Registry of Patients With Psoriasis Who are Receiving, or are Candidates for, Conventional Systemic Treatments or Biologic Agents
October 2012 | Volume 11 | Issue 10 | Original Article | 1210 | Copyright © October 2012
Background: Long-term observational studies can better characterize the impact of systemic agents on psoriasis.
Objective: To describe the on-going Psoriasis Longitudinal Assessmen...
Read MoreJDD: Celebrating 10 Years of Publishing Excellence
October 2012 | Volume 11 | Issue 10 | Editorials | 1150 | Copyright © October 2012
Ustekinumab for Treatment of Plaque Psoriasis in a Patient With Down Syndrome
August 2012 | Volume 11 | Issue 8 | Case Reports | 1000 | Copyright © August 2012
Down syndrome (DS) is the most common chromosomal disorder and a major cause of mental retardation. Down syndrome phenotype is complex and may present a combination of dysmorphic features, congenital ...
Read MoreOpen Label Study to Evaluate the Efficacy of Re-Treatment With Etanercept in Patients With Psoriasis
August 2012 | Volume 11 | Issue 8 | Original Article | 950 | Copyright © August 2012
Background: Etanercept has been used to treat chronic plaque psoriasis. Previously reported data demonstrated that some patients experienced secondary failure and frequently rotational-switch t...
Read MoreUstekinumab Improves Health-Related Quality of Life in Korean and Taiwanese Patients With Moderate to Severe Psoriasis: Results from the PEARL Trial
August 2012 | Volume 11 | Issue 8 | Original Article | 943 | Copyright © August 2012
Background: The PEARL study showed that the proportion of psoriasis patients achieving the primary endpoint (at least 75% improvement from baseline to week 12 in the Psoriasis Area and Severity...
Read MoreTreatment of Nail Psoriasis With TNF-α or IL12/23 Inhibitors
August 2012 | Volume 11 | Issue 8 | Original Article | 939 | Copyright © August 2012
Nail psoriasis appears to be an important source of psoriatic morbidity through physical impairment, pain, and cosmetic disturbances. Conventional treatment is often unsatisfactory. A systematic revie...
Read MoreJAK Inhibitors in Psoriasis: A Promising New Treatment Modality
August 2012 | Volume 11 | Issue 8 | Original Article | 913 | Copyright © August 2012
Background: Inflammatory cytokines play a crucial role in the pathophysiology of psoriasis. New therapies are targeting Janus kinases (JAKs), enzymes involved with transduction of cytokine rece...
Read MoreThe Safety of Ustekinumab in Psoriasis
August 2012 | Volume 11 | Issue 8 | Original Article | 907 | Copyright © August 2012
Ustekinumab is effective in the treatment of a variety of autoimmune conditions including psoriasis. As a relatively new therapeutic agent, its long-term effects are still under investigation. Short-t...
Read MoreMessage from the Guest Editor
August 2012 | Volume 11 | Issue 8 | Editorials | 906 | Copyright © August 2012
Trichoscopy of Cicatricial Alopecia
June 2012 | Volume 11 | Issue 6 | Original Article | 753 | Copyright © June 2012
Background: Trichoscopy is widely used in differential diagnosis of non-cicatricial alopecia.
Objective: The aim of this prospective study was to identify possible characteristic t...
Read MoreClinical Trial Review
April 2012 | Volume 11 | Issue 4 | Features | 548 | Copyright © April 2012
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select...
Read MorePIPELINE PREVIEWS
April 2012 | Volume 11 | Issue 4 | Features | 546 | Copyright © April 2012
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from th...
Read MoreTreatment of Generalized Vitiligo With Anti-TNF-α Agents
April 2012 | Volume 11 | Issue 4 | Case Reports | 534 | Copyright © April 2012
Background: Although the exact pathogenesis of vitiligo is not fully understood, it appears to be an autoimmune disease. It is hypothesized that tumor necrosis factor alpha (TNF-α) plays ...
Read MoreCLINICAL TRIAL REVIEW
March 2012 | Volume 11 | Issue 3 | Features | 424 | Copyright © March 2012
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select ...
Read MoreAn Update on the Long-Term Safety Experience of Ustekinumab: Results From the Psoriasis Clinical Development Program With up to Four Years of Follow-Up
March 2012 | Volume 11 | Issue 3 | Original Article | 300 | Copyright © March 2012
Background: The efficacy and safety profile of ustekinumab with up to three years of exposure suggested a favorable benefit-risk profile in patients with moderate to severe psoriasis.
Read More Ustekinumab: A Review in the Treatment of Plaque Psoriasis and Psoriatic Arthritis
February 2012 | Volume 11 | Issue 2 | Original Article | 160 | Copyright © February 2012
Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably affects the skin, nails, and joints. In September 2009, ustekinumab (Stelara®), a monoclonal antibody that ta...
Read MorePIPELINE PREVIEWS
October 2011 | Volume 10 | Issue 10 | Features | 1215 | Copyright © October 2011
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from the...
Read MoreTattoo Sites and Psoriasis
October 2011 | Volume 10 | Issue 10 | Case Reports | 1199 | Copyright © October 2011
The Koebner phenomenon refers to the development of lesions in response to injury of previously uninvolved skin. It occu...
Read MoreIncreased Prevalence of Psychiatric Disorders and Health Care-Associated Costs Among Patients With Moderate-to-Severe Psoriasis
August 2011 | Volume 10 | Issue 8 | Original Article | 843 | Copyright © August 2011
Objective: To characterize the prevalence of psychiatric disorders in patients with moderate-to-severe psoriasis and compare health care costs between patients with and without psychiatric como...
Read More